Cyclic Nucleotide Phosphodiesterases, Type 4
"Cyclic Nucleotide Phosphodiesterases, Type 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclic nucleotide phosphodiesterase subfamily that is found predominantly in inflammatory cells and may play a role in the regulation of CELL-MEDIATED IMMUNITY. The enzyme family includes over twenty different variants that occur due to multiple ALTERNATIVE SPLICING of the mRNA of at least four different genes.
| Descriptor ID |
D054703
|
| MeSH Number(s) |
D08.811.277.352.640.150.400 D12.644.360.008.400 D12.776.476.008.400
|
| Concept/Terms |
Cyclic Nucleotide Phosphodiesterases, Type 4- Cyclic Nucleotide Phosphodiesterases, Type 4
- Phosphodiesterase-4
- Phosphodiesterase IV
- PDE4 Phosphodiesterases
- Phosphodiesterases, PDE4
- Cyclic Nucleotide Phosphodiesterase PDE4 Family
- Phosphodiesterase 4
- Type 4 Cyclic Nucleotide Phosphodiesterase
|
Below are MeSH descriptors whose meaning is more general than "Cyclic Nucleotide Phosphodiesterases, Type 4".
Below are MeSH descriptors whose meaning is more specific than "Cyclic Nucleotide Phosphodiesterases, Type 4".
This graph shows the total number of publications written about "Cyclic Nucleotide Phosphodiesterases, Type 4" by people in this website by year, and whether "Cyclic Nucleotide Phosphodiesterases, Type 4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclic Nucleotide Phosphodiesterases, Type 4" by people in Profiles.
-
Systematic identification of regulatory variants associated with cancer risk. Genome Biol. 2017 10 23; 18(1):194.
-
Ferulic acid alleviates Aß25-35- and lipopolysaccharide-induced PC12 cellular damage: a potential role in Alzheimer's disease by PDE inhibition. Int J Clin Pharmacol Ther. 2015 Oct; 53(10):828-37.
-
RNA interference-mediated phosphodiesterase 4D splice variants knock-down in the prefrontal cortex produces antidepressant-like and cognition-enhancing effects. Br J Pharmacol. 2013 Feb; 168(4):1001-14.
-
A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy. Pharmacogenet Genomics. 2012 Apr; 22(4):229-35.
-
An evolutionary analysis of cAMP-specific Phosphodiesterase 4 alternative splicing. BMC Evol Biol. 2010 Aug 11; 10:247.
-
Lack of association between variations of PDE4D and ischemic stroke in the Japanese population. Stroke. 2009 Apr; 40(4):1245-51.
-
Changes in NMDA receptor-induced cyclic nucleotide synthesis regulate the age-dependent increase in PDE4A expression in primary cortical cultures. Brain Res. 2007 May 29; 1149:58-68.
-
A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology. 2007 Jan; 132(1):76-86.
-
Phosphodiesterase 4 inhibition of beta2-integrin adhesion caused by leukotriene B4 and TNF-alpha in human neutrophils. Eur Respir J. 2006 Nov; 28(5):920-8.
-
Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest. 2006 Jan; 129(1):56-66.